# Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

> **NCT05269316** · PHASE1,PHASE2 · RECRUITING · sponsor: **Impact Therapeutics, Inc.** · enrollment: 61 (estimated)

## Conditions studied

- Solid Tumor
- Advanced Solid Tumor

## Interventions

- **DRUG:** IMP9064

## Key facts

- **NCT ID:** NCT05269316
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269316, "Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05269316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*